Volume 84, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Helminth infections influence the clinical response to certain diseases and are associated with delayed healing time of patients with cutaneous leishmaniasis (CL) caused by . We conducted a randomized, double-blind, placebo-controlled clinical trial to examine the role of early versus deferred treatment of intestinal helminth infection on the clinical course of patients with CL treated with pentavalent antimony. (Clinicaltrials.gov number NCT00469495). A total of 90 patients were enrolled, 51.1% ( = 23) of control patients had persistent lesions at Day 90, compared with 62.2% ( = 28) in the treatment group (difference 11.1%, 95% confidence interval = −9.1–30.0%). There was no statistically significant difference in overall time to cure between groups, although there was a tendency for shorter cure times in the control group. This study shows that early introduction of antihelminthic therapy does not improve clinical outcome in patients co-infected with helminths and .


Article metrics loading...

Loading full text...

Full text loading...



  1. Jones T, Johnson W, Barretto A, Lago E, Marsden P, , 1987. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis . J Infect Dis 156: 7383.[Crossref]
  2. Correia D, Macêdo V, Carvalho E, Barral A, Magalhães A, Abreu M, Orge M, Marsden P, , 1996. Comparative study of meglumine antimonate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Vianna) braziliensis . Revista da Sociedade Brasiliera de Medicina Tropical 29: 447453.[Crossref]
  3. Romero G, Guerra M, Paes M, Macedo V, , 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65: 456465.
  4. Bacellar O, Lessa H, Schriefer A, Machado P, Jesus A, Dutra WO, Gollob KJ, Carvalho EM, , 2002. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70: 67346740.[Crossref]
  5. Ribeiro-de-Jesus A, Almeida R, Lessa H, Bacellar O, Carvalho E, , 1998. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31: 143148.[Crossref]
  6. Bittencourt A, Barral A, , 1991. Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 86: 5156.[Crossref]
  7. Machado P, Araújo C, daSilva A, Almeida RP, D'Oliveira A, Jr Bittencourt A, Carvalho EM, , 2002. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 34: e69e73.[Crossref]
  8. DaCruz A, Oliveira MD, Luca PD, Mendonca S, Coutinho S, , 1996. Tumor necrosis factor-alpha in human American tegumentary leishmaniasis. Mem Inst Oswaldo Cruz 91: 225229.[Crossref]
  9. Almeida R, D'Oliveira A, Jr Machado P, Bacellar O, Ko AI, de Jesus A, Mobashery N, Brito Santos J, Carvalho EM, , 1999. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 180: 17351737.[Crossref]
  10. Lessa H, Machado P, Lima F, Cruz A, Bacellar O, Guerreiro J, Carvalho EM, , 2001. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 8789.
  11. Medeiros JM, Figueiredo JP, Almeida MC, Matos MA, Araújo MI, Cruz AA, Atta AM, Rego MA, de Jesus AR, Taketomi EA, Carvalho EM, , 2003. Schistosoma mansoni infection is associated with a reduced course of asthma. J Allergy Clin Immunol 111: 947951.[Crossref]
  12. Summers RW, Elliott DE, Qadir K, Urban JF, Thompson R, Weinstock JV, , 2003. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98: 20342041.[Crossref]
  13. Maizels RM, , 2005. Infections and allergy–helminths, hygiene and host immune regulation. Curr Opin Immunol 17: 656661.[Crossref]
  14. Araujo M, Hoppe B, Medeiros M, Jr Alcântara L, Almeida MC, Schriefer A, Oliveira R, Kruschewsky R, Figueiredo J, Cruz A, Carvalho E, , 2004. Impaired T helper 2 response to aeroallergen in helminth-infected patients with asthma. J Infect Dis 190: 17971803.[Crossref]
  15. O'Neal SE, Guimarães LH, Machado PR, Alcântara L, Morgan DJ, Passos S, Glesby MJ, Carvalho EM, , 2007. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 195: 142148.[Crossref]
  16. Schriefer A, Goes-Neto A, Guimaraes LH, Carvalho LP, Almeida RP, Machado PR, Lessa HA, de Jesus AR, Riley LW, Carvalho EM, , 2004. Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis. Infect Immun 72: 508514.[Crossref]
  17. Reed S, Badaró R, Masur H, Carvalho E, Lorenco R, Lisboa A, Teixeira R, Johnson W, Jr Jones T, , 1986. Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg 35: 7985.
  18. NIAID Division of AIDS Toxicity Grading Scale. Guidance, Compliance & Regulatory Information (Biologics). Available at: http://www.fda.gov/cber/guidelines.htm. Accessed September 14, 2007.
  19. Rocha H, Kirk J, Hearey C, Jr, 1971. Prolonged Salmonella bacteremia in patients with Schistosoma mansoni infection. Arch Intern Med 128: 254257.[Crossref]

Data & Media loading...

  • Received : 27 Jul 2010
  • Accepted : 04 Jan 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error